TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07175428: A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-AT

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1200 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,673,200

Rescue Site Savings

+$4,415,600

Unlock Full NCT07175428 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07175428 Rescue Dossier →